Related Experiment Video
Updated: Aug 27, 2025

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Safety of routine childhood vaccine coadministration versus separate vaccination
Jorgen Bauwens1,2, Simon de Lusignan3,4, Yonas Ghebremichael Weldesselassie5
1University of Basel Children's Hospital, Basel, Switzerland bauwens.jorgen@gmail.com.
Insights
Coadministering routine childhood vaccines is generally safe, with most adverse events following immunization (AEFI) showing no significant difference compared to separate vaccinations. Some specific vaccine combinations showed increased risks for certain AEFI, warranting further investigation into severity.
Area of Science:
- Pediatrics
- Immunology
- Public Health
Background:
- Vaccine coadministration is increasingly used to improve delivery efficiency for healthcare systems and patients.
- Understanding the safety profile of coadministered vaccines compared to separate administration is crucial for public health policy.
Purpose of the Study:
- To compare the safety of 20 vaccine coadministrations with separate vaccinations.
- To identify specific adverse events following immunization (AEFI) associated with coadministration.
Main Methods:
- An observational cohort study using real-world immunisation and AEFI data from 2008-2018.
- Self-controlled case series method applied to calculate relative incidence ratios (RIR) for AEFI.
Main Results:
- No significant difference in AEFI for 72% of coadministrations; 17% occurred less frequently, and 11% more frequently.
- Amplifying interaction effects observed for specific AEFI with certain multi-vaccine coadministrations (e.g., fever, rash, gastrointestinal, respiratory events).
- No indication that unscheduled coadministrations are less safe than scheduled ones.
Conclusions:
- Real-world data support the coadministration of routine childhood vaccines as per the immunisation schedule.
- Further research is needed to fully understand the severity and burden of AEFI following vaccine coadministration.
Introduction:
As new vaccines are developed more vaccine coadministrations vaccines are being offered to make delivery more practical for health systems and patients. We compared the safety of coadministered vaccines with separate vaccination for 20 coadministrations by considering nine types of adverse events following immunisation (AEFI).
Methods:
Real-life immunisation and adverse event data for this observational cohort study were extracted from the Oxford-Royal College of General Practitioners Research and Surveillance Centre for children registered in the database between 2008 and 2018. We applied the self-controlled case series method to calculate relative incidence ratios (RIR) for AEFI. These RIRs compare the RI of AEFI following coadministration with the RI following separate administration of the same vaccines.
Results:
We assessed 3 518 047 adverse events and included 5 993 290 vaccine doses given to 958 591 children. 17% of AEFI occurred less and 11% more frequently following coadministration than would have been expected based on the RIs following separate vaccinations, while there was no significant difference for 72% of AEFI. We found amplifying interaction effects for AEFI after five coadministrations comprising three vaccines: for fever (RIR 1.93 (95% CI 1.63 to 2.29)), rash (RIR 1.49 (95% CI 1.29 to 1.74)), gastrointestinal events (RIR 1.31 (95% CI 1.14 to 1.49)) and respiratory events (RIR 1.27 (1.17-1.38)) following DTaP/IPV/Hib+MenC+ PCV; gastrointestinal events (RIR 1.65 (95% CI 1.35 to 2.02)) following DTaP/IPV/Hib+MenC+ RV; fever (RIR 1.44 (95% CI 1.09 to 1.90)) and respiratory events (RIR 1.40 (95% CI 1.25 to 1.57)) following DTaP/IPV/Hib+PCV+ RV; gastrointestinal (RIR 1.48 (95% CI 1.20 to 1.82)) and respiratory events (RIR 1.43 (95% CI 1.26 to 1.63)) following MMR+Hib/MenC+PCV; gastrointestinal events (RIR 1.68 (95% CI 1.07 to 2.64)) and general symptoms (RIR 11.83 (95% CI 1.28 to 109.01)) following MMR+MenC+PCV. Coadministration of MMR+PCV led to more fever (RIR 1.91 (95% CI 1.83 to 1.99)), neurological events (RIR 2.04 (95% CI 1.67 to 2.49)) and rash (RIR 1.06 (95% CI 1.01 to 1.11)) compared with separate administration, DTaP/IPV/Hib+MMR to more musculoskeletal events (RIR 3.56 (95% CI 1.21 to 10.50)) and MMR+MenC to more fever (RIR 1.58 (95% CI 1.37 to 1.82)). There was no indication that unscheduled coadministrations are less safe than scheduled coadministrations.
Conclusion:
Real-life RIRs of AEFI justify coadministering routine childhood vaccines according to the immunisation schedule. Further research into the severity of AEFI following coadministration is required for a complete understanding of the burden of these AEFI.
More Related Videos
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Related Concept Videos
Vaccinations
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Teratogenicity
Factors Affecting Drug Response: Overview
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...